Cardio Vascular Medical Device Corp. (OTC: CVSL), a leading developer of advanced cardiovascular surgery technology, today released a brief shareholders update.
Cardio Vascular Medical Device holds a US patent for an innovative next-generation "steerable guidewire" applicable for all angioplasty (PCTA) procedures. The guidewire has a unique opportunity to become the guidewire of choice for surgeons throughout the world.
The technology hinges on a bendable tip that improves guidewire performance, enables faster procedure completion, and provides cost benefits for patients as well as healthcare providers.
"Cardio Vascular Medical Device has developed a technology that provides several advantages over the current guidewires being employed in angioplasty procedures," stated Eli Gonen, CEO of Cardio Vascular Medical Device Corp. "And with well over 7 million angioplasties performed each year, the global annual potential addressable market in excess of $500 million."
Cardio Vascular Medical Device is working diligently to complete the development of the guidewire, in preparation for full commercial distribution.
Cardio Vascular Medical Device Corp. plans to keep public shareholders informed of all upcoming company developments.
Anger damages blood vessel function, raising heart disease risk